Luis G Hernandez (Luis Hernandez)

Publication Activity (10 Years)

Years Active: 2024-2024
Publications (10 Years): 26

Top Topics

Systematic Review

Metastatic Colorectal Cancer

Palliative Care

Small Cell Lung Cancer

Top Venues

Journal of comparative effectiveness research

PharmacoEconomics

Journal of medical economics

This page only lists publications with an associated author ORCID identifier.

Publications

Andreas Freitag, Grammati Sarri, An Ta, Laura Gurskyte, Dasha Cherepanov, Luis G Hernandez
A Systematic Review of Modeling Approaches to Evaluate Treatments for Relapsed Refractory Multiple Myeloma: Critical Review and Considerations for Future Health Economic Models. PharmacoEconomics 42 (9) (2024)
Victoria Federico Paly, Arvind Dasari, Joleen Hubbard, Tanios Bekaii-Saab, Thihan Padukkavidana, Luis G Hernandez
Adverse event costs of systemic therapies for metastatic colorectal cancer previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy and biologics in the US. Journal of comparative effectiveness research 13 (8) (2024)
Victoria Federico Paly, Shujun Li, Pratishtha Khanduri, Alemseged Ayele Asfaw, Denise Zou, Luis G Hernandez
Budget impact analysis of introducing fruquintinib for metastatic colorectal cancer previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy and biologics in the United States from the payer perspective. Journal of medical economics (2024)
Grammati Sarri, Luis G Hernandez
The maze of real-world evidence frameworks: from a desert to a jungle! An environmental scan and comparison across regulatory and health technology assessment agencies. Journal of comparative effectiveness research (2024)
Victoria Federico Paly, Arvind Dasari, Joleen Hubbard, Tanios Bekaii-Saab, Thihan Padukkavidana, Luis G Hernandez
Adverse event costs of systemic therapies for metastatic colorectal cancer previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy and biologics in the US. Journal of comparative effectiveness research 13 (8) (2024)
Grammati Sarri, Luis G Hernandez
The maze of real-world evidence frameworks: from a desert to a jungle! An environmental scan and comparison across regulatory and health technology assessment agencies. Journal of comparative effectiveness research 13 (9) (2024)
Angie Raad, Maria Rizzo, Katherine Appiah, Isabella Kearns, Luis G Hernandez
Critical Examination of Modeling Approaches Used in Economic Evaluations of First-Line Treatments for Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Mutations: A Systematic Literature Review. PharmacoEconomics 42 (5) (2024)
Grammati Sarri, Maria Rizzo, Sheela Upadhyaya, Victoria Federico Paly, Luis G Hernandez
Navigating the unknown: how to best 'reflect' standard of care in indications without a dedicated treatment pathway in health technology assessment submissions. Journal of comparative effectiveness research 13 (2) (2024)
Angie Raad, Maria Rizzo, Katherine Appiah, Isabella Kearns, Luis G Hernandez
Critical Examination of Modeling Approaches Used in Economic Evaluations of First-Line Treatments for Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Mutations: A Systematic Literature Review. PharmacoEconomics 42 (5) (2024)
Angie Raad, Maria Rizzo, Katherine Appiah, Isabella Kearns, Luis G Hernandez
Critical Examination of Modeling Approaches Used in Economic Evaluations of First-Line Treatments for Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Mutations: A Systematic Literature Review. PharmacoEconomics (2024)
Victoria Federico Paly, Arvind Dasari, Joleen Hubbard, Tanios Bekaii-Saab, Thihan Padukkavidana, Luis G Hernandez
Adverse event costs of systemic therapies for metastatic colorectal cancer previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy and biologics in the US. Journal of comparative effectiveness research 13 (8) (2024)
Grammati Sarri, Maria Rizzo, Sheela Upadhyaya, Victoria Federico Paly, Luis G Hernandez
Navigating the unknown: how to best 'reflect' standard of care in indications without a dedicated treatment pathway in health technology assessment submissions. Journal of comparative effectiveness research 13 (2) (2024)
Grammati Sarri, Maria Rizzo, Sheela Upadhyaya, Victoria Federico Paly, Luis G Hernandez
Navigating the unknown: how to best 'reflect' standard of care in indications without a dedicated treatment pathway in health technology assessment submissions. Journal of comparative effectiveness research 13 (2) (2024)
Grammati Sarri, Luis G Hernandez
The maze of real-world evidence frameworks: from a desert to a jungle! An environmental scan and comparison across regulatory and health technology assessment agencies. Journal of comparative effectiveness research 13 (9) (2024)
Victoria Federico Paly, Arvind Dasari, Joleen Hubbard, Tanios Bekaii-Saab, Thihan Padukkavidana, Luis G Hernandez
Adverse event costs of systemic therapies for metastatic colorectal cancer previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy and biologics in the US. Journal of comparative effectiveness research 13 (8) (2024)
Victoria Federico Paly, Shujun Li, Pratishtha Khanduri, Alemseged Ayele Asfaw, Denise Zou, Luis G Hernandez
Budget impact analysis of introducing fruquintinib for metastatic colorectal cancer previously treated with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy and biologics in the United States from the payer perspective. Journal of medical economics 27 (1) (2024)
Grammati Sarri, Maria Rizzo, Sheela Upadhyaya, Victoria Federico Paly, Luis G Hernandez
Navigating the unknown: how to best 'reflect' standard of care in indications without a dedicated treatment pathway in health technology assessment submissions. Journal of comparative effectiveness research 13 (2) (2024)
Angie Raad, Maria Rizzo, Katherine Appiah, Isabella Kearns, Luis G Hernandez
Critical Examination of Modeling Approaches Used in Economic Evaluations of First-Line Treatments for Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Mutations: A Systematic Literature Review. PharmacoEconomics 42 (5) (2024)
Victoria Federico Paly, Arvind Dasari, Joleen Hubbard, Tanios Bekaii-Saab, Thihan Padukkavidana, Luis G Hernandez
Adverse event costs of systemic therapies for metastatic colorectal cancer previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy and biologics in the US. Journal of comparative effectiveness research (2024)
Andreas Freitag, Grammati Sarri, An Ta, Laura Gurskyte, Dasha Cherepanov, Luis G Hernandez
A Systematic Review of Modeling Approaches to Evaluate Treatments for Relapsed Refractory Multiple Myeloma: Critical Review and Considerations for Future Health Economic Models. PharmacoEconomics 42 (9) (2024)
Victoria Federico Paly, Arvind Dasari, Joleen Hubbard, Tanios Bekaii-Saab, Thihan Padukkavidana, Luis G Hernandez
Adverse event costs of systemic therapies for metastatic colorectal cancer previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy and biologics in the US. Journal of comparative effectiveness research (2024)
Andreas Freitag, Grammati Sarri, An Ta, Laura Gurskyte, Dasha Cherepanov, Luis G Hernandez
A Systematic Review of Modeling Approaches to Evaluate Treatments for Relapsed Refractory Multiple Myeloma: Critical Review and Considerations for Future Health Economic Models. PharmacoEconomics (2024)
Andreas Freitag, Grammati Sarri, An Ta, Laura Gurskyte, Dasha Cherepanov, Luis G Hernandez
A Systematic Review of Modeling Approaches to Evaluate Treatments for Relapsed Refractory Multiple Myeloma: Critical Review and Considerations for Future Health Economic Models. PharmacoEconomics 42 (9) (2024)
Angie Raad, Maria Rizzo, Katherine Appiah, Isabella Kearns, Luis G Hernandez
Critical Examination of Modeling Approaches Used in Economic Evaluations of First-Line Treatments for Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Mutations: A Systematic Literature Review. PharmacoEconomics 42 (5) (2024)
Grammati Sarri, Maria Rizzo, Sheela Upadhyaya, Victoria Federico Paly, Luis G Hernandez
Navigating the unknown: how to best 'reflect' standard of care in indications without a dedicated treatment pathway in health technology assessment submissions. Journal of comparative effectiveness research 13 (2) (2024)
Angie Raad, Maria Rizzo, Katherine Appiah, Isabella Kearns, Luis G Hernandez
Critical Examination of Modeling Approaches Used in Economic Evaluations of First-Line Treatments for Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Mutations: A Systematic Literature Review. PharmacoEconomics 42 (5) (2024)